Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 16 studies | 33% ± 12% | |
lung | 14 studies | 30% ± 13% | |
intestine | 7 studies | 23% ± 5% | |
brain | 7 studies | 25% ± 6% | |
lymph node | 5 studies | 37% ± 7% | |
uterus | 4 studies | 33% ± 4% | |
breast | 4 studies | 28% ± 4% | |
liver | 4 studies | 31% ± 9% | |
kidney | 3 studies | 29% ± 5% | |
bone marrow | 3 studies | 26% ± 4% | |
prostate | 3 studies | 21% ± 2% | |
skin | 3 studies | 37% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 472.53 | 1439 / 1445 | 100% | 9.64 | 183 / 183 |
lung | 100% | 1254.61 | 578 / 578 | 97% | 5.08 | 1118 / 1155 |
breast | 100% | 650.31 | 458 / 459 | 92% | 5.27 | 1030 / 1118 |
stomach | 99% | 380.94 | 355 / 359 | 92% | 4.02 | 262 / 286 |
bladder | 100% | 680.24 | 21 / 21 | 85% | 4.10 | 426 / 504 |
pancreas | 99% | 334.30 | 325 / 328 | 85% | 2.65 | 152 / 178 |
intestine | 99% | 499.18 | 960 / 966 | 80% | 2.60 | 423 / 527 |
uterus | 100% | 479.25 | 170 / 170 | 79% | 3.44 | 361 / 459 |
ovary | 100% | 1046.68 | 180 / 180 | 78% | 1.57 | 334 / 430 |
thymus | 100% | 612.31 | 651 / 653 | 73% | 1.94 | 444 / 605 |
prostate | 100% | 466.89 | 245 / 245 | 70% | 1.73 | 352 / 502 |
skin | 99% | 1013.29 | 1798 / 1809 | 63% | 1.32 | 297 / 472 |
kidney | 90% | 278.54 | 80 / 89 | 62% | 1.65 | 561 / 901 |
liver | 99% | 301.40 | 224 / 226 | 25% | 0.44 | 103 / 406 |
adrenal gland | 99% | 337.87 | 256 / 258 | 23% | 0.40 | 54 / 230 |
spleen | 100% | 731.43 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 1.41 | 1 / 1 |
adipose | 100% | 848.59 | 1202 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 1709.48 | 920 / 929 | 0% | 0 | 0 / 0 |
blood vessel | 96% | 371.49 | 1278 / 1335 | 0% | 0 | 0 / 0 |
brain | 47% | 132.56 | 1238 / 2642 | 48% | 0.85 | 339 / 705 |
muscle | 84% | 179.34 | 678 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 79% | 4.11 | 23 / 29 |
tonsil | 0% | 0 | 0 / 0 | 78% | 4.38 | 35 / 45 |
heart | 77% | 231.49 | 662 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 31% | 0.55 | 25 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006954 | Biological process | inflammatory response |
GO_0033554 | Biological process | cellular response to stress |
GO_0010629 | Biological process | negative regulation of gene expression |
GO_0045087 | Biological process | innate immune response |
GO_0034097 | Biological process | response to cytokine |
GO_0007249 | Biological process | canonical NF-kappaB signal transduction |
GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
GO_0032688 | Biological process | negative regulation of interferon-beta production |
GO_0038061 | Biological process | non-canonical NF-kappaB signal transduction |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005654 | Cellular component | nucleoplasm |
GO_0071159 | Cellular component | NF-kappaB complex |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0001228 | Molecular function | DNA-binding transcription activator activity, RNA polymerase II-specific |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_0003700 | Molecular function | DNA-binding transcription factor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | REL |
Protein name | Proto-oncogene c-Rel REL proto-oncogene, NF-kB subunit |
Synonyms | |
Description | FUNCTION: Proto-oncogene that may play a role in differentiation and lymphopoiesis. NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. The NF-kappa-B heterodimer RELA/p65-c-Rel is a transcriptional activator. |
Accessions | ENST00000699192.1 ENST00000295025.12 [Q04864-1] ENST00000394479.4 [Q04864-2] A0A8V8TPL7 A0A8V8TMU9 Q04864 ENST00000699191.1 A0A8V8TMW2 ENST00000699193.1 |